Brind.

Athira Pharma is developing ATH-1105, a potential therapy for ALS and other neurodegenerative diseases.

1 report, 1 independent Updated Aug 8
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Athira Pharma is developing ATH-1105, a potential therapy for ALS and other neurodegenerative diseases.

Who's involved

What this event is mainly about
Athira PharmaAls

Keep exploring

The entities involved

  • Athira Pharma

    company in Seattle, United States

    Nothing else this week.

  • Als

    river in Vienna

    Nothing else this week.

Related events

Coverage

Newest first; wire copies grouped
  • GlobeNewswireAthira Pharma Reports Second Quarter 2025 Financial Results and Provides Business Update Data from Phase 1 clinical trial of ATH-1105 in healthy volunteers showed a favorable safety and tolerability